Modality
siRNA
MOA
WEE1i
Target
PD-1
Pathway
Cell Cycle
ThymomaPompePV
Development Pipeline
Preclinical
~Oct 2013
→ ~Jan 2015
Phase 1
~Apr 2015
→ ~Jul 2016
Phase 2
~Oct 2016
→ ~Jan 2018
Phase 3
~Apr 2018
→ ~Jul 2019
NDA/BLA
~Oct 2019
→ ~Jan 2021
Approved
Apr 2021
→ Nov 2026
ApprovedCurrent
NCT08221130
1,896 pts·Thymoma
2021-12→TBD·Completed
NCT05618874
348 pts·PV
2021-04→2026-11·Not yet recruiting
NCT04335443
2,361 pts·PV
2022-09→2026-03·Not yet recruiting
+1 more trial
5,865 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-03-093w agoNDA· PV
2026-03-221w agoPh3 Readout· PV
2026-11-027mo awayPh3 Readout· PV
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Approved
Not yet…
Approved
Complet…
Approved
Not yet…
Approved
Not yet…
Catalysts
NDA
2026-03-09 · 3w ago
PV
Ph3 Readout
2026-03-22 · 1w ago
PV
Ph3 Readout
2026-11-02 · 7mo away
PV
CompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08221130 | Approved | Thymoma | Completed | 1896 | UPDRS |
| NCT05618874 | Approved | PV | Not yet recr... | 348 | EDSS |
| NCT04335443 | Approved | PV | Not yet recr... | 2361 | ORR |
| NCT07770800 | Approved | PV | Not yet recr... | 1260 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 |